Compare STRS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | OABI |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 237.4M |
| IPO Year | 1994 | N/A |
| Metric | STRS | OABI |
|---|---|---|
| Price | $29.47 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 29.4K | ★ 657.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 512.50 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $29,914,000.00 | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $20.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.35 | $1.22 |
| 52 Week High | $32.93 | $2.22 |
| Indicator | STRS | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 61.96 |
| Support Level | $29.50 | $1.47 |
| Resistance Level | $31.62 | $1.70 |
| Average True Range (ATR) | 0.59 | 0.08 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 56.54 | 89.71 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.